๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics in Drug Discovery

โœ Scribed by Ana Ruiz-Garcia; Marival Bermejo; Aaron Moss; Vicente G. Casabo


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
365 KB
Volume
97
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

โœฆ Synopsis


The aim of this current review is to summarize the present status of pharmacokinetics in Drug Discovery. The review is structured into four sections. The first section is a general overview of what we understand by pharmacokinetics and the different LADMET aspects: Liberation, Absorption, Distribution, Metabolism, Excretion, and Toxicity. The second section highlights the different computational or in silico approaches to estimate/predict one or several aspects of the pharmacokinetic profile of a discovery lead compound. The third section discusses the most commonly used in vitro methodologies. The fourth and last section examines the various approaches employed towards the pharmacokinetic assessment of discovery molecules; including all the LADME processes, discussing the different mathematical methodologies available to establish the PK profile of a test compound; what the main differences are and what should be the criteria for using one or another mathematical approach. The major conclusion of this review is that the use of the appropriate preclinical assays has a key role in the long-term viability of a pharmaceutical company since applying the right tools early in discovery will play a key role in determining the company's ability to discover novel safe and effective therapeutics to patients as quickly as possible.


๐Ÿ“œ SIMILAR VOLUMES


Pharmacokinetics and metabolism in early
โœ Dennis A Smith; Han van de Waterbeemd ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 663 KB

The need for high-throughput approaches in absorption, distribution, metabolism and excretion studies is driven by the impact of high-speed chemistry and pharmacological screening. Perhaps an even greater impact is that these studies will, in the future, provide large data sets that can be used to p

Pharmacokinetics and its role in small m
โœ Graham R. Jang; Robert Z. Harris; David T. Lau ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 233 KB

## Abstract Pharmacokinetics (PK), which describes the disposition of a drug in the body, should be a primary consideration in the selection of a drug candidate, ultimately contributing to its eventual clinical success or failure. Accordingly, a sound understanding of PK concepts and an appreciatio

N-in-1 dosing pharmacokinetics in drug d
โœ Kan He; Mingxin Qian; Harvey Wong; Stephen A. Bai; Bing He; Bernice Brogdon; Jam ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 185 KB

N-in-1 (or cassette) dosing pharmacokinetics (PK) has been used in drug discovery for rapid assessment of PK properties of new chemical entities. However, because of potential for drug-drug interactions this procedure is still controversial. This study was to retrospectively evaluate the N-in-1 dosi

Bioinformatics in drug discovery
โœ David T. Kingsbury ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 96 KB ๐Ÿ‘ 1 views

It is estimated that when the Human Genome Project's DNA sequencing phase reaches it peak steady-state, the production rate will be approximately 70 to 80 "new" genes each day, every day. This estimate is based on genomic sequencing and not expressed sequence tags (ESTs) or full-length cDNA sequenci

Proteomics in drug discovery
โœ Jonathan Burbaum; Gabriela M Tobal ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 67 KB

Drug discovery is a prolonged process that uses a variety of tools from diverse fields. To accelerate the process, a number of biotechnologies, including genomics, proteomics and a number of cellular and organismic methodologies, have been developed. Proteomics development faces interdisciplinary ch